Biogen

Biogen

Team Size
1–10
Employees
Pulse 2.0

Biogen (BIIB) Stock: $270 Target And Outperform Rating

Pulse 2.0

Biogen (BIIB) Stock Price: Why It Increased Over 2% Today

MedCity News

Biogen gets in tune with MedRhythms to develop new digital therapeutic for MS

Pulse 2.0

Biogen (BIIB) Stock: $265 Price Target And Overweight Rating

MedCity News

Biogen pulls Alzheimer’s drug application in Europe as EMA calls data insufficient

Pulse 2.0

Biogen (BIIB) Stock: $265 Price Target And Overweight Rating

Pulse 2.0

Biogen (BIIB) Stock: Why The Price Increased Today

Pulse 2.0

Biogen (BIIB) Stock: $219 Price Target And Equal-Weight Rating

Pulse 2.0

Biogen (BIIB) Stock: $262 Price Target And Buy Rating

Pulse 2.0

Biogen (BIIB) Stock: $185 Price Target From Wedbush

MedCity News

Final CMS decision limits coverage of Biogen’s Aduhelm to those in clinical trials

Pulse 2.0

Biogen (BIIB) Stock: $225 Price Target From BofA

Pulse 2.0

Biogen (BIIB) Stock: $238 Price Target And Market Perform Rating

Pulse 2.0

Biogen (BIIB) Stock: $238 Price Target And Market Perform Rating

Pulse 2.0

Biogen (BIIB) Stock: $290 Price Target From Needham

Pulse 2.0

Biogen (BIIB) Stock: Why The Price Fell Today

Quartz

Biogen’s Alzheimer drug Aduhelm proves drug prices are a lie

Pulse 2.0

Biogen Stock (BIIB): $325 Price Target From Jefferies

Pulse 2.0

Biogen Stock (BIIB): Why The Price Dropped Today

MedCity News

CMS proposes limited coverage of Biogen Alzheimer’s drug, only in clinical trials